Previous studies suggest that CD46, a membrane regulator of complement activation, is overexpressed on human malignancies including colorectal, cervical, and pancreatic carcinomas compared with their normal counterparts (33–36). The gene discussed is CD46; the disease is exocrine pancreatic carcinoma.